カテゴリー： Market Monitor Global, 世界, 医療/バイオ

降圧剤の世界市場見通し2023年-2029年

◆英語タイトル：Antihypertensive Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5681）

◆商品コード：MMG23JU5681
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：128
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Antihypertensive Market 調査レポートは次の情報を含め、グローバルにおけるの降圧剤市場規模と予測を収録しています。・世界の降圧剤市場：売上、2018年-2023年、2024年-2029年
・世界の降圧剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の降圧剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「利尿薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

降圧剤のグローバル主要企業は、Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、降圧剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の降圧剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の降圧剤市場：タイプ別市場シェア、2022年
・利尿薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシン受容体遮断薬（ARB）、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬

世界の降圧剤市場：用途別、2018年-2023年、2024年-2029年
世界の降圧剤市場：用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン薬局、その他

世界の降圧剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の降圧剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における降圧剤のグローバル売上、2018年-2023年
・主要企業における降圧剤のグローバル売上シェア、2022年
・主要企業における降圧剤のグローバル販売量、2018年-2023年
・主要企業における降圧剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceutical

*************************************************************

・調査・分析レポートの概要
降圧剤市場の定義
市場セグメント
世界の降圧剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の降圧剤市場規模
世界の降圧剤市場規模：2022年 VS 2029年
世界の降圧剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの降圧剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の降圧剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：利尿薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシン受容体遮断薬（ARB）、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬
降圧剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、オンライン薬局、その他
降圧剤の用途別グローバル売上・予測

・地域別市場分析
地域別降圧剤市場規模 2022年と2029年
地域別降圧剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceutical
...

This report aims to provide a comprehensive presentation of the global market for Antihypertensive, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive. This report contains market size and forecasts of Antihypertensive in global, including the following market information:
Global Antihypertensive Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Antihypertensive Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Antihypertensive companies in 2022 (%)
The global Antihypertensive market was valued at US$ 19810 million in 2022 and is projected to reach US$ 22820 million by 2029, at a CAGR of 2.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Increase in blood pressure is measured in terms of systolic and diastolic blood pressure exerted by blood on the wall of artery and hence it is also termed as arterial hypertension. Reduction in blood pressure minimizes the risk of heart failure, ischaemic heart diseases, dementia and mortality due to hypertension.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihypertensive manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihypertensive Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, by Type, 2022 (%)
Diuretics
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
Calcium Channel Blockers
Beta Blockers
Alpha Blockers
Vasodilators & Renin Inhibitors
Global Antihypertensive Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Global Antihypertensive Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antihypertensive revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Antihypertensive revenues share in global market, 2022 (%)
Key companies Antihypertensive sales in global market, 2018-2023 (Estimated), (Units)
Key companies Antihypertensive sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Norvatis
Merck & Co.
Sanofi
AstraZeneca
GSK
Daiichi-Sankyo
Boehringer-Ingelheim
Bayer
Johnson & Johnson
Bristol-Myers Squibb
Tekeda
Ranbaxy Laboratories
Shihuida Pharm
Second Pharmaceutical
Lupin Limited.
Yangtze River Pharmaceutical
Hengrui Medicine
Qilu Pharmaceutical
HUALON
Dawnrays
HISUN Pharmceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antihypertensive, market overview.
Chapter 2: Global Antihypertensive market size in revenue and volume.
Chapter 3: Detailed analysis of Antihypertensive manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antihypertensive in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Antihypertensive capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Antihypertensive Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antihypertensive Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antihypertensive Overall Market Size
2.1 Global Antihypertensive Market Size: 2022 VS 2029
2.2 Global Antihypertensive Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Antihypertensive Sales: 2018-2029
3 Company Landscape
3.1 Top Antihypertensive Players in Global Market
3.2 Top Global Antihypertensive Companies Ranked by Revenue
3.3 Global Antihypertensive Revenue by Companies
3.4 Global Antihypertensive Sales by Companies
3.5 Global Antihypertensive Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Antihypertensive Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Antihypertensive Product Type
3.8 Tier 1, Tier 2 and Tier 3 Antihypertensive Players in Global Market
3.8.1 List of Global Tier 1 Antihypertensive Companies
3.8.2 List of Global Tier 2 and Tier 3 Antihypertensive Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Antihypertensive Market Size Markets, 2022 & 2029
4.1.2 Diuretics
4.1.3 Angiotensin Converting Enzyme (ACE) Inhibitors
4.1.4 Angiotensin Receptor Blockers (ARBs)
4.1.5 Calcium Channel Blockers
4.1.6 Beta Blockers
4.1.7 Alpha Blockers
4.1.8 Vasodilators & Renin Inhibitors
4.2 By Type – Global Antihypertensive Revenue & Forecasts
4.2.1 By Type – Global Antihypertensive Revenue, 2018-2023
4.2.2 By Type – Global Antihypertensive Revenue, 2024-2029
4.2.3 By Type – Global Antihypertensive Revenue Market Share, 2018-2029
4.3 By Type – Global Antihypertensive Sales & Forecasts
4.3.1 By Type – Global Antihypertensive Sales, 2018-2023
4.3.2 By Type – Global Antihypertensive Sales, 2024-2029
4.3.3 By Type – Global Antihypertensive Sales Market Share, 2018-2029
4.4 By Type – Global Antihypertensive Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Antihypertensive Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.1.5 Others
5.2 By Application – Global Antihypertensive Revenue & Forecasts
5.2.1 By Application – Global Antihypertensive Revenue, 2018-2023
5.2.2 By Application – Global Antihypertensive Revenue, 2024-2029
5.2.3 By Application – Global Antihypertensive Revenue Market Share, 2018-2029
5.3 By Application – Global Antihypertensive Sales & Forecasts
5.3.1 By Application – Global Antihypertensive Sales, 2018-2023
5.3.2 By Application – Global Antihypertensive Sales, 2024-2029
5.3.3 By Application – Global Antihypertensive Sales Market Share, 2018-2029
5.4 By Application – Global Antihypertensive Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Antihypertensive Market Size, 2022 & 2029
6.2 By Region – Global Antihypertensive Revenue & Forecasts
6.2.1 By Region – Global Antihypertensive Revenue, 2018-2023
6.2.2 By Region – Global Antihypertensive Revenue, 2024-2029
6.2.3 By Region – Global Antihypertensive Revenue Market Share, 2018-2029
6.3 By Region – Global Antihypertensive Sales & Forecasts
6.3.1 By Region – Global Antihypertensive Sales, 2018-2023
6.3.2 By Region – Global Antihypertensive Sales, 2024-2029
6.3.3 By Region – Global Antihypertensive Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Antihypertensive Revenue, 2018-2029
6.4.2 By Country – North America Antihypertensive Sales, 2018-2029
6.4.3 US Antihypertensive Market Size, 2018-2029
6.4.4 Canada Antihypertensive Market Size, 2018-2029
6.4.5 Mexico Antihypertensive Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Antihypertensive Revenue, 2018-2029
6.5.2 By Country – Europe Antihypertensive Sales, 2018-2029
6.5.3 Germany Antihypertensive Market Size, 2018-2029
6.5.4 France Antihypertensive Market Size, 2018-2029
6.5.5 U.K. Antihypertensive Market Size, 2018-2029
6.5.6 Italy Antihypertensive Market Size, 2018-2029
6.5.7 Russia Antihypertensive Market Size, 2018-2029
6.5.8 Nordic Countries Antihypertensive Market Size, 2018-2029
6.5.9 Benelux Antihypertensive Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Antihypertensive Revenue, 2018-2029
6.6.2 By Region – Asia Antihypertensive Sales, 2018-2029
6.6.3 China Antihypertensive Market Size, 2018-2029
6.6.4 Japan Antihypertensive Market Size, 2018-2029
6.6.5 South Korea Antihypertensive Market Size, 2018-2029
6.6.6 Southeast Asia Antihypertensive Market Size, 2018-2029
6.6.7 India Antihypertensive Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Antihypertensive Revenue, 2018-2029
6.7.2 By Country – South America Antihypertensive Sales, 2018-2029
6.7.3 Brazil Antihypertensive Market Size, 2018-2029
6.7.4 Argentina Antihypertensive Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Antihypertensive Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Antihypertensive Sales, 2018-2029
6.8.3 Turkey Antihypertensive Market Size, 2018-2029
6.8.4 Israel Antihypertensive Market Size, 2018-2029
6.8.5 Saudi Arabia Antihypertensive Market Size, 2018-2029
6.8.6 UAE Antihypertensive Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Antihypertensive Major Product Offerings
7.1.4 Pfizer Antihypertensive Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Norvatis
7.2.1 Norvatis Company Summary
7.2.2 Norvatis Business Overview
7.2.3 Norvatis Antihypertensive Major Product Offerings
7.2.4 Norvatis Antihypertensive Sales and Revenue in Global (2018-2023)
7.2.5 Norvatis Key News & Latest Developments
7.3 Merck & Co.
7.3.1 Merck & Co. Company Summary
7.3.2 Merck & Co. Business Overview
7.3.3 Merck & Co. Antihypertensive Major Product Offerings
7.3.4 Merck & Co. Antihypertensive Sales and Revenue in Global (2018-2023)
7.3.5 Merck & Co. Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Antihypertensive Major Product Offerings
7.4.4 Sanofi Antihypertensive Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Company Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Antihypertensive Major Product Offerings
7.5.4 AstraZeneca Antihypertensive Sales and Revenue in Global (2018-2023)
7.5.5 AstraZeneca Key News & Latest Developments
7.6 GSK
7.6.1 GSK Company Summary
7.6.2 GSK Business Overview
7.6.3 GSK Antihypertensive Major Product Offerings
7.6.4 GSK Antihypertensive Sales and Revenue in Global (2018-2023)
7.6.5 GSK Key News & Latest Developments
7.7 Daiichi-Sankyo
7.7.1 Daiichi-Sankyo Company Summary
7.7.2 Daiichi-Sankyo Business Overview
7.7.3 Daiichi-Sankyo Antihypertensive Major Product Offerings
7.7.4 Daiichi-Sankyo Antihypertensive Sales and Revenue in Global (2018-2023)
7.7.5 Daiichi-Sankyo Key News & Latest Developments
7.8 Boehringer-Ingelheim
7.8.1 Boehringer-Ingelheim Company Summary
7.8.2 Boehringer-Ingelheim Business Overview
7.8.3 Boehringer-Ingelheim Antihypertensive Major Product Offerings
7.8.4 Boehringer-Ingelheim Antihypertensive Sales and Revenue in Global (2018-2023)
7.8.5 Boehringer-Ingelheim Key News & Latest Developments
7.9 Bayer
7.9.1 Bayer Company Summary
7.9.2 Bayer Business Overview
7.9.3 Bayer Antihypertensive Major Product Offerings
7.9.4 Bayer Antihypertensive Sales and Revenue in Global (2018-2023)
7.9.5 Bayer Key News & Latest Developments
7.10 Johnson & Johnson
7.10.1 Johnson & Johnson Company Summary
7.10.2 Johnson & Johnson Business Overview
7.10.3 Johnson & Johnson Antihypertensive Major Product Offerings
7.10.4 Johnson & Johnson Antihypertensive Sales and Revenue in Global (2018-2023)
7.10.5 Johnson & Johnson Key News & Latest Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Company Summary
7.11.2 Bristol-Myers Squibb Antihypertensive Business Overview
7.11.3 Bristol-Myers Squibb Antihypertensive Major Product Offerings
7.11.4 Bristol-Myers Squibb Antihypertensive Sales and Revenue in Global (2018-2023)
7.11.5 Bristol-Myers Squibb Key News & Latest Developments
7.12 Tekeda
7.12.1 Tekeda Company Summary
7.12.2 Tekeda Antihypertensive Business Overview
7.12.3 Tekeda Antihypertensive Major Product Offerings
7.12.4 Tekeda Antihypertensive Sales and Revenue in Global (2018-2023)
7.12.5 Tekeda Key News & Latest Developments
7.13 Ranbaxy Laboratories
7.13.1 Ranbaxy Laboratories Company Summary
7.13.2 Ranbaxy Laboratories Antihypertensive Business Overview
7.13.3 Ranbaxy Laboratories Antihypertensive Major Product Offerings
7.13.4 Ranbaxy Laboratories Antihypertensive Sales and Revenue in Global (2018-2023)
7.13.5 Ranbaxy Laboratories Key News & Latest Developments
7.14 Shihuida Pharm
7.14.1 Shihuida Pharm Company Summary
7.14.2 Shihuida Pharm Business Overview
7.14.3 Shihuida Pharm Antihypertensive Major Product Offerings
7.14.4 Shihuida Pharm Antihypertensive Sales and Revenue in Global (2018-2023)
7.14.5 Shihuida Pharm Key News & Latest Developments
7.15 Second Pharmaceutical
7.15.1 Second Pharmaceutical Company Summary
7.15.2 Second Pharmaceutical Business Overview
7.15.3 Second Pharmaceutical Antihypertensive Major Product Offerings
7.15.4 Second Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.15.5 Second Pharmaceutical Key News & Latest Developments
7.16 Lupin Limited.
7.16.1 Lupin Limited. Company Summary
7.16.2 Lupin Limited. Business Overview
7.16.3 Lupin Limited. Antihypertensive Major Product Offerings
7.16.4 Lupin Limited. Antihypertensive Sales and Revenue in Global (2018-2023)
7.16.5 Lupin Limited. Key News & Latest Developments
7.17 Yangtze River Pharmaceutical
7.17.1 Yangtze River Pharmaceutical Company Summary
7.17.2 Yangtze River Pharmaceutical Business Overview
7.17.3 Yangtze River Pharmaceutical Antihypertensive Major Product Offerings
7.17.4 Yangtze River Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.17.5 Yangtze River Pharmaceutical Key News & Latest Developments
7.18 Hengrui Medicine
7.18.1 Hengrui Medicine Company Summary
7.18.2 Hengrui Medicine Business Overview
7.18.3 Hengrui Medicine Antihypertensive Major Product Offerings
7.18.4 Hengrui Medicine Antihypertensive Sales and Revenue in Global (2018-2023)
7.18.5 Hengrui Medicine Key News & Latest Developments
7.19 Qilu Pharmaceutical
7.19.1 Qilu Pharmaceutical Company Summary
7.19.2 Qilu Pharmaceutical Business Overview
7.19.3 Qilu Pharmaceutical Antihypertensive Major Product Offerings
7.19.4 Qilu Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.19.5 Qilu Pharmaceutical Key News & Latest Developments
7.20 HUALON
7.20.1 HUALON Company Summary
7.20.2 HUALON Business Overview
7.20.3 HUALON Antihypertensive Major Product Offerings
7.20.4 HUALON Antihypertensive Sales and Revenue in Global (2018-2023)
7.20.5 HUALON Key News & Latest Developments
7.21 Dawnrays
7.21.1 Dawnrays Company Summary
7.21.2 Dawnrays Business Overview
7.21.3 Dawnrays Antihypertensive Major Product Offerings
7.21.4 Dawnrays Antihypertensive Sales and Revenue in Global (2018-2023)
7.21.5 Dawnrays Key News & Latest Developments
7.22 HISUN Pharmceutical
7.22.1 HISUN Pharmceutical Company Summary
7.22.2 HISUN Pharmceutical Business Overview
7.22.3 HISUN Pharmceutical Antihypertensive Major Product Offerings
7.22.4 HISUN Pharmceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.22.5 HISUN Pharmceutical Key News & Latest Developments
8 Global Antihypertensive Production Capacity, Analysis
8.1 Global Antihypertensive Production Capacity, 2018-2029
8.2 Antihypertensive Production Capacity of Key Manufacturers in Global Market
8.3 Global Antihypertensive Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Antihypertensive Supply Chain Analysis
10.1 Antihypertensive Industry Value Chain
10.2 Antihypertensive Upstream Market
10.3 Antihypertensive Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Antihypertensive Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Antihypertensive in Global Market
Table 2. Top Antihypertensive Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Antihypertensive Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Antihypertensive Revenue Share by Companies, 2018-2023
Table 5. Global Antihypertensive Sales by Companies, (Units), 2018-2023
Table 6. Global Antihypertensive Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Antihypertensive Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Antihypertensive Product Type
Table 9. List of Global Tier 1 Antihypertensive Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antihypertensive Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Antihypertensive Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Antihypertensive Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Antihypertensive Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Antihypertensive Sales (Units), 2018-2023
Table 15. By Type - Global Antihypertensive Sales (Units), 2024-2029
Table 16. By Application – Global Antihypertensive Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Antihypertensive Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Antihypertensive Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Antihypertensive Sales (Units), 2018-2023
Table 20. By Application - Global Antihypertensive Sales (Units), 2024-2029
Table 21. By Region – Global Antihypertensive Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Antihypertensive Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Antihypertensive Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Antihypertensive Sales (Units), 2018-2023
Table 25. By Region - Global Antihypertensive Sales (Units), 2024-2029
Table 26. By Country - North America Antihypertensive Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Antihypertensive Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Antihypertensive Sales, (Units), 2018-2023
Table 29. By Country - North America Antihypertensive Sales, (Units), 2024-2029
Table 30. By Country - Europe Antihypertensive Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Antihypertensive Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Antihypertensive Sales, (Units), 2018-2023
Table 33. By Country - Europe Antihypertensive Sales, (Units), 2024-2029
Table 34. By Region - Asia Antihypertensive Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Antihypertensive Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Antihypertensive Sales, (Units), 2018-2023
Table 37. By Region - Asia Antihypertensive Sales, (Units), 2024-2029
Table 38. By Country - South America Antihypertensive Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Antihypertensive Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Antihypertensive Sales, (Units), 2018-2023
Table 41. By Country - South America Antihypertensive Sales, (Units), 2024-2029
Table 42. By Country - Middle East & Africa Antihypertensive Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Antihypertensive Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Antihypertensive Sales, (Units), 2018-2023
Table 45. By Country - Middle East & Africa Antihypertensive Sales, (Units), 2024-2029
Table 46. Pfizer Company Summary
Table 47. Pfizer Antihypertensive Product Offerings
Table 48. Pfizer Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Norvatis Company Summary
Table 51. Norvatis Antihypertensive Product Offerings
Table 52. Norvatis Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Norvatis Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Antihypertensive Product Offerings
Table 56. Merck & Co. Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Sanofi Company Summary
Table 59. Sanofi Antihypertensive Product Offerings
Table 60. Sanofi Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Sanofi Key News & Latest Developments
Table 62. AstraZeneca Company Summary
Table 63. AstraZeneca Antihypertensive Product Offerings
Table 64. AstraZeneca Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. AstraZeneca Key News & Latest Developments
Table 66. GSK Company Summary
Table 67. GSK Antihypertensive Product Offerings
Table 68. GSK Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. GSK Key News & Latest Developments
Table 70. Daiichi-Sankyo Company Summary
Table 71. Daiichi-Sankyo Antihypertensive Product Offerings
Table 72. Daiichi-Sankyo Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Daiichi-Sankyo Key News & Latest Developments
Table 74. Boehringer-Ingelheim Company Summary
Table 75. Boehringer-Ingelheim Antihypertensive Product Offerings
Table 76. Boehringer-Ingelheim Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Boehringer-Ingelheim Key News & Latest Developments
Table 78. Bayer Company Summary
Table 79. Bayer Antihypertensive Product Offerings
Table 80. Bayer Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Bayer Key News & Latest Developments
Table 82. Johnson & Johnson Company Summary
Table 83. Johnson & Johnson Antihypertensive Product Offerings
Table 84. Johnson & Johnson Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Johnson & Johnson Key News & Latest Developments
Table 86. Bristol-Myers Squibb Company Summary
Table 87. Bristol-Myers Squibb Antihypertensive Product Offerings
Table 88. Bristol-Myers Squibb Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. Bristol-Myers Squibb Key News & Latest Developments
Table 90. Tekeda Company Summary
Table 91. Tekeda Antihypertensive Product Offerings
Table 92. Tekeda Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 93. Tekeda Key News & Latest Developments
Table 94. Ranbaxy Laboratories Company Summary
Table 95. Ranbaxy Laboratories Antihypertensive Product Offerings
Table 96. Ranbaxy Laboratories Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 97. Ranbaxy Laboratories Key News & Latest Developments
Table 98. Shihuida Pharm Company Summary
Table 99. Shihuida Pharm Antihypertensive Product Offerings
Table 100. Shihuida Pharm Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 101. Shihuida Pharm Key News & Latest Developments
Table 102. Second Pharmaceutical Company Summary
Table 103. Second Pharmaceutical Antihypertensive Product Offerings
Table 104. Second Pharmaceutical Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 105. Second Pharmaceutical Key News & Latest Developments
Table 106. Lupin Limited. Company Summary
Table 107. Lupin Limited. Antihypertensive Product Offerings
Table 108. Lupin Limited. Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 109. Lupin Limited. Key News & Latest Developments
Table 110. Yangtze River Pharmaceutical Company Summary
Table 111. Yangtze River Pharmaceutical Antihypertensive Product Offerings
Table 112. Yangtze River Pharmaceutical Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 113. Yangtze River Pharmaceutical Key News & Latest Developments
Table 114. Hengrui Medicine Company Summary
Table 115. Hengrui Medicine Antihypertensive Product Offerings
Table 116. Hengrui Medicine Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 117. Hengrui Medicine Key News & Latest Developments
Table 118. Qilu Pharmaceutical Company Summary
Table 119. Qilu Pharmaceutical Antihypertensive Product Offerings
Table 120. Qilu Pharmaceutical Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 121. Qilu Pharmaceutical Key News & Latest Developments
Table 122. HUALON Company Summary
Table 123. HUALON Antihypertensive Product Offerings
Table 124. HUALON Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 125. HUALON Key News & Latest Developments
Table 126. Dawnrays Company Summary
Table 127. Dawnrays Antihypertensive Product Offerings
Table 128. Dawnrays Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 129. Dawnrays Key News & Latest Developments
Table 130. HISUN Pharmceutical Company Summary
Table 131. HISUN Pharmceutical Antihypertensive Product Offerings
Table 132. HISUN Pharmceutical Antihypertensive Sales (Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 133. HISUN Pharmceutical Key News & Latest Developments
Table 134. Antihypertensive Production Capacity (Units) of Key Manufacturers in Global Market, 2021-2023 (Units)
Table 135. Global Antihypertensive Capacity Market Share of Key Manufacturers, 2021-2023
Table 136. Global Antihypertensive Production by Region, 2018-2023 (Units)
Table 137. Global Antihypertensive Production by Region, 2024-2029 (Units)
Table 138. Antihypertensive Market Opportunities & Trends in Global Market
Table 139. Antihypertensive Market Drivers in Global Market
Table 140. Antihypertensive Market Restraints in Global Market
Table 141. Antihypertensive Raw Materials
Table 142. Antihypertensive Raw Materials Suppliers in Global Market
Table 143. Typical Antihypertensive Downstream
Table 144. Antihypertensive Downstream Clients in Global Market
Table 145. Antihypertensive Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Antihypertensive Segment by Type in 2022
Figure 2. Antihypertensive Segment by Application in 2022
Figure 3. Global Antihypertensive Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Antihypertensive Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Antihypertensive Revenue, 2018-2029 (US$, Mn)
Figure 7. Antihypertensive Sales in Global Market: 2018-2029 (Units)
Figure 8. The Top 3 and 5 Players Market Share by Antihypertensive Revenue in 2022
Figure 9. By Type - Global Antihypertensive Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Antihypertensive Revenue Market Share, 2018-2029
Figure 11. By Type - Global Antihypertensive Sales Market Share, 2018-2029
Figure 12. By Type - Global Antihypertensive Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Antihypertensive Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Antihypertensive Revenue Market Share, 2018-2029
Figure 15. By Application - Global Antihypertensive Sales Market Share, 2018-2029
Figure 16. By Application - Global Antihypertensive Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Antihypertensive Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Antihypertensive Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Antihypertensive Revenue Market Share, 2018-2029
Figure 20. By Region - Global Antihypertensive Sales Market Share, 2018-2029
Figure 21. By Country - North America Antihypertensive Revenue Market Share, 2018-2029
Figure 22. By Country - North America Antihypertensive Sales Market Share, 2018-2029
Figure 23. US Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Antihypertensive Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Antihypertensive Sales Market Share, 2018-2029
Figure 28. Germany Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 29. France Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Antihypertensive Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Antihypertensive Sales Market Share, 2018-2029
Figure 37. China Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 41. India Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Antihypertensive Revenue Market Share, 2018-2029
Figure 43. By Country - South America Antihypertensive Sales Market Share, 2018-2029
Figure 44. Brazil Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Antihypertensive Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Antihypertensive Sales Market Share, 2018-2029
Figure 48. Turkey Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Antihypertensive Revenue, (US$, Mn), 2018-2029
Figure 52. Global Antihypertensive Production Capacity (Units), 2018-2029
Figure 53. The Percentage of Production Antihypertensive by Region, 2022 VS 2029
Figure 54. Antihypertensive Industry Value Chain
Figure 55. Marketing Channels

※参考情報

降圧剤とは、血圧を下げるために使用される薬剤の総称であり、特に高血圧症（高血圧）を治療する目的で用いられます。高血圧は、心臓病や脳卒中、腎不全などの重篤な合併症を引き起こすリスク因子とされるため、適切な治療が必要です。降圧剤は、様々な機序で血圧を低下させるための薬剤群であり、患者の状態や血圧の度合いに応じて使用されます。

降圧剤の特徴として、まず第一に、作用の仕組みが異なる多様な薬剤が存在する点が挙げられます。これにより、患者の個々の健康状態や他の疾患との関連を考慮しながら、最適な治療法を選択することができます。また、降圧剤は一般的に内服薬として処方されることが多いですが、場合によっては静脈内投与などの形式もあります。

降圧剤の種類には、主に以下のようなものがあります。第一に、ACE阻害薬（アンジオテンシン変換酵素阻害薬）が挙げられます。これらの薬剤は、血圧を上昇させるホルモンであるアンジオテンシンIIの生成を抑制し、その結果、血管を拡張させることによって血圧を低下させます。ACE阻害薬は高血圧のみならず、心不全や糖尿病性腎症の治療にも使用されることがあります。

次に、ARBs（アンジオテンシンII受容体拮抗薬）があります。これらは、アンジオテンシンIIが受容体に結合するのを防ぐことによって同様の効果を発揮します。ARBsは通常、ACE阻害薬と同様の適応症がありますが、ACE阻害薬による咳や副作用が少なく、耐容性が良好な場合が多いとされています。

カルシウム拮抗薬も重要な種類の一つです。これらの薬剤は、心臓や血管の平滑筋細胞におけるカルシウムの流入を抑えることにより、心拍数の低下や血管の拡張を促進します。カルシウム拮抗薬は、狭心症や不整脈の治療にも使用されることがあります。

利尿薬も降圧剤の中で広く使われているカテゴリーです。これらの薬剤は腎臓による水分やナトリウムの排泄を促進し、血液量を減少させることで血圧を低下させます。特に高血圧が水分貯留に関連している患者に対して効果的です。

β-ブロッカーも降圧効果がある薬剤の一つです。これらの薬剤は心拍数を減少させ、心臓の負担を軽減することによって血圧を下げます。心疾患の患者には特に有効で、心筋梗塞後の予防にも使用されます。

降圧剤の用途には、高血圧の治療だけではなく、心不全、心房細動、狭心症、腎疾患などの治療においても重要な役割を果たします。高血圧が原因となる合併症を防ぐためには、長期的な管理が必要であり、降圧剤の使用が不可欠です。

最新の研究によれば、降圧剤の使用は、単独療法だけでなく、複数の薬剤を組み合わせた治療（併用療法）が推奨されることが多くなっています。これは、異なる作用機序を持つ薬剤を使用することで、より効果的に血圧を管理できる可能性があるためです。

関連技術として、血圧のモニタリング技術も重要です。家庭用の血圧計やウェアラブルデバイスによる血圧管理は、患者自身が血圧のコントロールを意識する助けとなります。これにより、医療従事者は患者の状態をより正確に把握し、必要に応じて治療法の調整を行いやすくなります。また、生活習慣の改善や食事療法と組み合わせた包括的なアプローチが、高血圧管理において推奨されています。

降圧剤の使用においては、患者の個別性に配慮することが重要です。年齢、性別、合併症の有無により、同じ降圧剤でも効果や副作用の出方が大きく異なることがあります。そのため、医師は患者の状況を詳細に評価し、最適な薬剤を選択することが求められます。

降圧剤には副作用も存在し、例えばACE阻害薬に伴う咳やARBsのめまい、利尿薬による電解質異常などが挙げられます。これらの副作用は、個々の患者の反応によって異なるため、定期的なフォローアップが不可欠です。また、患者が自己管理をしやすいよう、医療従事者が血圧測定の方法や副作用のモニタリングについても指導することが大切です。

今後の研究により、新しい降圧剤や治療法が開発されることが期待されています。例えば、最近では心臓の健康を意識した食事療法や、フィットネスプログラムといった生活習慣の改善が重要視されており、薬物療法との併用が望まれます。また、バイオテクノロジーを利用した新しい薬剤の開発も進んでおり、ますます多様な治療の選択肢が提供されることでしょう。

このように、降圧剤は高血圧の治療に欠かせない薬剤であり、様々な種類や作用機序を持つ薬剤が存在することによって、患者に合わせた個別の治療が可能となっています。降圧剤の適切な使用と並行して、生活習慣の改善や最新の医療技術の活用が重要であり、これにより高血圧による合併症の予防が期待されます。高血圧の管理は、患者自身の理解と協力が不可欠なため、教育と啓発活動も非常に重要な要素となります。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 降圧剤の世界市場見通し2023年-2029年(Antihypertensive Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

降圧剤の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp